PepGen Inc.
PEPGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company carries a $174.5M market cap, placing it firmly in the micro-cap category. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Market Cap
$174.5M
Beta
2.01
P/E (TTM)
—
P/E (Fwd)
-2.38
EPS (TTM)
$-1.01
EPS (Fwd)
$-1.06
ROE
-75.4%
ROA
-39.1%
Cash
$117.2M
Total Debt
$16.1M
Free CF
-$43.3M
52W Change
-44.9%
Annual Financials
Cash vs Debt
Where PEPG stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, PEPG finished 7.66% above its 150-day moving average ($2.35) and 21.91% below its 200-day moving average ($3.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PEPG overbought or oversold?
At the October 16, 2026 close, PEPG's RSI(14) was 48.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $117.2M in cash comfortably exceeding the $16.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$43.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -75.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta above 1.5, PEPG tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, PEPG has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence PepGen Inc.'s trajectory.